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Distance saturation product predicts
health–related quality of life among sarcoidosis
patients
Julie M Bourbonnais, Subramanian Malaisamy, Bhavinkumar D Dalal, Priyan C Samarakoon, Swapna R Parikh and
Lobelia Samavati*
Abstract
Background: Sarcoidosis is a chronic disease with different phenotypic manifestations. Health-related quality of life
is an important aspect in sarcoidosis, yet difficult to measure. The objective of this study was to identify clinical
markers predictive of poor quality of life in sarcoidosis patients that can be followed over time and targeted for
intervention.
Methods: We assessed the quality of life of 162 patients with confirmed sarcoidosis in a prospective, cross-sectional
study using the Sarcoidosis Health Questionnaire (SHQ) and Short Form-36 Health Survey (SF-36). We evaluated the
validity of these questionnaires and sought to identify variables that would best explain the performance scores of
the patients.
Results: On multivariate regression analyses, the very best composite model to predict total scores from both
surveys was a model containing the distance-saturation product and Borg Dyspnea Scale score at the end of a
6-min walk test. This model could better predict SF-36 scores (R2 = 0.33) than SHQ scores (R2 = 0.24). Substitution of
distanced walked in 6 min for the distance-saturation product in this model resulted in a lesser ability to predict
both scores (R2 = 0.26 for SF-36; R2 = 0.22 for SHQ).
Conclusions: Both the SHQ and SF-36 surveys are valuable tools in the assessment of health-related quality of life
in sarcoidosis patients. The best model to predict quality of life among these patients, as determined by regression
analyses, included the distance-saturation product and Borg score after the 6-min walk test. Both variables represent
easily obtainable clinical parameters that can be followed over time and targeted for intervention.
Keywords: Sarcoidosis, Health- related quality of life, 6-min walk test, Distance-saturation product
Background
Sarcoidosis is a chronic, multisystem disease with a
highly variable natural history, prognosis, and response
to treatment [1]. Symptoms may include cough, dyspnea,
fatigue, and pain, all of which can be disabling and may
impair the quality of life (QoL) [2].
Health-related quality of life (HRQoL) is defined as an
individual’s overall satisfaction with life and functional
status as affected by the disease. Despite the complex
nature of QoL, HRQoL measurements attempt to assess
the impact of a disease and/or therapeutic intervention
on QoL.
Measures of HRQoL are classified as either disease-
specific or generic [3-5]. Generic measures are consid-
ered less precise than disease-specific in their ability to
assess the different aspects of a disease, but these mea-
sures may capture unanticipated side effects of therapies.
Measures of HRQoL have been validated for multiple
diseases, including sarcoidosis. However, there is also a
need for reliable physiological measures that can reflect
HRQoL. Identification of these parameters is important
since modification of these variables through targeted
interventions may improve the QoL of patients.
* Correspondence: lsamavat@med.wayne.edu
Department of Medicine, Division of Pulmonary, Critical Care and Sleep,
Wayne State University School of Medicine and Detroit Medical Center,
Detroit, MI 48201, USA
© 2012 Bourbonnais et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Bourbonnais et al. Health and Quality of Life Outcomes 2012, 10:67
http://www.hqlo.com/content/10/1/67
There is a paucity of studies addressing physiologic
predictors as surrogates for measurement of HRQoL.
Several routine clinical measures, including pulmonary
function tests (PFTs) and the 6-min walk test (6MWT),
may serve such purpose. Previous studies have not con-
sistently demonstrated strong correlation between
HRQoL scores and the severity of airflow limitation in
some respiratory diseases, such as chronic obstructive
pulmonary disease (COPD) [6, 7]. Elements derived
from the 6MWT have been shown to fairly accurately
predict morbidity and mortality in a variety of heart and
lung diseases and may represent a better predictor of
HRQoL scores [8-18]. The distance-saturation product
(DSP) is calculated from walking distance and the lowest
oxygen saturation occurring during 6MWT [17]. The
DSP was shown to be a better predictor of poor out-
come in patients with idiopathic pulmonary fibrosis
(IPF) than the individual elements used in its calculation
[17].
The purpose of this study is to identify measurable
clinical and physiological variables, which best correlate
with HRQoL and can be followed over time for targeted
intervention. We hypothesized that the measures derived
from the 6MWT are a better predictor of HRQoL mea-
sures than are PFTs. Additionally, we postulate that DSP
may be the most useful variable because it is a compos-
ite index and may more accurately reflect the multiorgan
involvement of sarcoidosis.
Methods
Patients with sarcoidosis were prospectively recruited
from the Sarcoidosis and Interstitial Lung Disease Clinic
at Wayne State University/Detroit Medical Center in
Detroit, Michigan. Sarcoidosis was diagnosed in all
patients using standard guidelines [19]. Adult patients
between 18 and 75 years with a biopsy proven diagnosis
of sarcoidosis for more than 6 months were invited to
participate between December 2005 and May 2008.
Patients who were pregnant and those who were organ
transplant recipients were excluded. Patients with known
COPD, active cancer, or severe cardiomyopathy were
excluded to avoid confounding comorbidities. Addition-
ally, patients were excluded if they were not fluent in
English or had physical impairments that prevented the
completion of questionnaires. The Institutional Review
Board of Wayne State University approved this study
and all patients provided informed consent.
Variables analyzed included chest radiography, PFT and
6MWT data. Chest radiography was available for most
patients and was interpreted as stage 0–4 [19, 20]. PFTs
were performed in a licensed laboratory following guide-
lines established by the American Thoracic Society [21].
All spirometry studies were performed as described previ-
ously [16]. Seventy nine percent of patients completed the
PFTs within 3 weeks (most within the same week), 16%
within 3 months, and less than 5% within 6 months of
completion of the questionnaires. All patients included in
analyses completed at least one 6MWT, performed by a
licensed respiratory therapist following a standardized
protocol [22]. Oxygen saturation was measured using a
finger probe pulse oximeter (NPB-40, Nellcor; Pleasanton,
CA). All subjects demonstrated a resting saturation of
more than 88% at initiation of testing. If the patients
required oxygen, the oxygen flow was maintained at their
baseline until completion of testing or adjusted based on
titration on exertion during home oxygen evaluation.
6MWT data included Borg Dyspnea Scale score (BDSS),
6-min walk distance (6MWD), and oxygen saturation. The
percent predicted 6MWD was calculated as described pre-
viously [23]. All 6MWT data were collected within 6 weeks
of completion of the questionnaires.
All participants self-administered two questionnaires,
the Sarcoidosis Health Questionnaire (SHQ) and the
Medical Outcomes Study 36-item Short Form survey
(SF-36) [3, 7, 24-29]. Using the online scoring system,
the individual scores were normalized and these values
were used for statistical analyses [30]. The SHQ is spe-
cific for sarcoidosis and has 29 questions with three
domains: daily, physical and emotional functioning [4].
The scores were calculated as previously described [4].
Continuous variables are expressed as mean± SEM.
Means were compared using the Student’s t test.
Discrete variables were compared using Fisher exact test.
Pearson correlation coefficient (r) was calculated to
measure the relationship between the clinical variables
and total SHQ and SF-36 scores. Multivariate analyses
were performed using a stepwise, descending method for
factors with significance on univariate analyses. Data
processing and analyses were performed using standard
statistical software (SPSS for Windows, version 15.0).
Statistical significance was defined as p value <0.05.
Results
One hundred and sixty two patients with a tissue proven
diagnosis of sarcoidosis consented to participate in the
study and completed both the SHQ and SF-36 question-
naires on the same day. Table 1 presents patient charac-
teristics. The average age of study group was 46, 76%
were nonsmokers, 72% were female (117) and 86% were
African American (139). The majority of patients had ac-
tive disease (72%), with 58% requiring steroid therapy
and 42% requiring immune modulating medications. In
152 patients (94%), pulmonary involvement was
observed. Thirty-one patients (19%) required oxygen
supplementation.
Table 2 shows the results of PFT and 6MWT. One hun-
dred fifty two patients had PFTs performed and 148 com-
pleted 6MWTs in the allotted time frame. The average
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distance walked was 427 m±106 m (range 105 m to
690 m). The DSP is a product of the walking distance at
6 min and the lowest oxygen saturation achieved during
the 6MWT [17]. The average DSP was 402 m%±108 m%
(range 103 m% to 662 m%).
The average SHQ score was 3.8 ± 1.1 and the average
SF-36 score was 45 ± 26. Using Pearson correlation, we
compared the validity of the SHQ with SF-36 question-
naires and their relationship was found to be significant
in all domains. Pearson correlation coefficients ranged
from a low of 0.72 for SF-36 Physical Component Score
(PCS) to a high of 0.78 for total score. Student’s t test
was used to compare the mean performance scores of
SHQ and SF-36 for patients with pulmonary hyperten-
sion (PH) and patients without PH. Patients with PH
demonstrated significantly lower scores (p< 0.05) in
total SF-36 (33 ± 12) as compared to those without PH
(45 ± 26). The SF-36 PCS scores between groups were
significantly different, 30 ± 2.7 for PH versus 39 ± 13 for
patients without PH (p = 0.007). Surprisingly, there were
no significant differences in the total SHQ scores be-
tween these two groups.
Pearson correlation was used to measure the relation-
ship between several clinical variables, the total SHQ
and SF-36 scores (Table 3). The most significant correla-
tions were found with elements derived from 6MWT
data. The highest correlation was found between DSP
and HRQoL scores as assessed by SF-36 (r = 0.47, p
< 0.01) or SHQ (r = 0.35, p< 0.01), respectively. The sec-
ond best correlation was found between the BDSS at
completion of the 6MWT and the total SF-36 score
(r =−0.45, p< 0.01) and the total SHQ score (r =−0.42, p
< 0.01). There was a lesser correlation between the
6MWD and the surveys (r = 0.42, p< 0.01 for SF-36 and
r = 0.34 p <0.01 for SHQ) and for oxygen saturation at
completion of 6MWT (r = 0.26, p< 0.01 for SF-36 and
r = 0.22, p< 0.01 for SHQ). Table 3 indicates all variables
analyzed had a smaller correlation with HRQoL scores
as measured by SHQ than by SF-36.
Overall, PFT values had a smaller correlation with the
HRQoL measures as compared to 6MWT values. The
highest correlations observed between SF-36 scores and
PFT values, were DLCO (r = 0.34, p< 0.01), FEV1
(r = 0.26, p< 0.01) and FVC (r = 0.26, p< 0.01). Interest-
ingly, all PFT values demonstrated lower correlations
with total SHQ scores (see Table 3).
On univariate analyses FEV1, DLCO, BDSS at 0 and
6 min, 6MWD and DSP were found to have a statisti-
cally significant relationship with questionnaire scores.
Multivariate regression analyses were performed using
Table 1 Patient characteristics
Age (Mean± SD) 45.9 ± 11.1 Disease, N (%)
BMI (Mean±SD) 32 ± 8.2 Inactive 45 (28)
Gender, N (%) Active/Symptomatic† 117 (72)
Male 45 (28) Organ Involvements N (%)
Female 117 (72) Lung 152 (94)
Race, N (%) Skin 49 (30)
African American 139 (86.8) Eye 43 (26)
White 21(13.2) Heart 11 (6)
CXR stage, N (%) Liver 18 (11)
0 13 (8.2) CNS 13 (6)
1 28 (17.7) PH* 28 (17)
2 65 (41.5) Medication, N (%)
3 24 (14) Steroidal 94 (58)
4 29(18.2) IMD{ 68 (42)
Non-smokers 123 (76) Steroidal + IMD 77 (47)
Values are means unless otherwise noted. N = number of patients,
parenthesis = percent.
*PH: pulmonary hypertension, diagnosed by right cardiac catheterization.
† Active defined as an increased requirement for steroid in last 6 months.
{ Immune modifying drugs like methotrexate, azathioprine and others.
Table 2 PFTs and 6-min Walk Test (6MWT)
Variables Mean± SD (range)
PFTs (N=152)
FEV1% 72± 20 (21–117)
FVC% 72± 18 (33–113)
TLC% 79± 17 (43–137)
DLCO% 62± 19 (21–107)
6MWT (N=148)
6MWD (m) 427 ± 106 (105–690)
6MWD (%) 75 ± 17 (23–111)
Oxygen saturation at 0 min 97 ± 2 (90–100)
Oxygen saturation at 6 min 93 ± 4.5 (78–100)
Borg Score (N=148)
Borg at 0 min 1.7 ± 1.7 (0–7)
Borg at 6 min 4.4 ± 2.3 (1–10)
DSP (N=148) (m%) 402 ± 108 (103–662)
N=Number of patients.
Table 3 Correlation between Total SF-36 and Total SHQ
Scores and Physiologic Variables
Total SHQ Score Total SF −36 Score
Variable r-value p-value r-value p-value
Borg at 6 min −0.42** < 0.01 −0.45** < 0.01
DSP 0.35** < 0.01 0.47** < 0.01
6MWD (m) 0.34** < 0.01 0.37** < 0.01
Borg at 0 min 0.31** < 0.01 0.374** < 0.01
O2 sat at 6min 0.23** < 0.01 0.26** < 0.01
DLCO (L mmHg/min) 0.30** < 0.01 0.34** < 0.01
FEV1(L) 0.12* < 0.01 0.26** < 0.01
** Correlation is significant at< 0.01 level (2-tailed test).
* Correlation is significant at< 0.05 level (2-tailed test).
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these significant variables. Because DSP is a derived
value from 6MWD, there is a high correlation between
these two independent variables. To obtain the best lin-
ear unbiased estimators, four sets of multivariate regres-
sion models were estimated. Regression analysis using
DSP with other independent variables as determined by
univariate analysis was conducted for both SF-36 and
SHQ to evaluate for the best model to account for the
scores of both measures. Estimated regression models
are reported in Table 4. After adjusting for age and BMI,
the only two variables that remained significant and
could reliably predict the HRQoL scores as measured by
SF-36 (R2 = 0.33) were DSP (p< 0.01; 95% CI: 0.082 -
0.02) and BDSS at 6 min (p = 0.049, 95% CI: -2.18 to -
1). When SHQ was used as the dependent variable, simi-
lar results were found but with a lower R2 value of 0.24
(DSP: p< 0.01, 95% CI: 0.002- 0.001; BDSS at 6 min p
< 0.01, 95% CI: -0.27 to −0.05). No other explanatory
variables were found to be significant. The results of the
regression analyses substituting 6MWD for DSP are
shown in Table 5. Table 5 indicates that only 6MWD (p
< 0.01) and BDSS (p = 0.04) were significant and could
reliably predict the HRQoL scores as measured by SF-36
(R2 = 0.26). Substituting SHQ for SF-36 scores, resulted
in similar findings but with a lower R2 value of 0.22
(6MWD, p = 0.01, Borg at 6 min p = 0.02).
Discussion
Several studies demonstrated poor HRQoL in patients
with respiratory diseases including sarcoidosis [2, 6, 7,
24-26, 29, 31-36]. Using two commonly employed health
related questionnaires we assessed the QoL of patients
with sarcoidosis and attempted to identify the physio-
logic parameters that best predict QoL measures.
Through statistical modeling, we determined that the
best prediction of QoL scores can be achieved by inte-
gration of two simple values obtained from the 6MWT:
DSP and BDSS at 6 min. Substitution of DSP value with
6MWD in the very same regression model resulted in a
lower R2. Others found a relationship between 6MWD
and HRQoL measures [18]. In our data set, oxygen
saturation at 6 min did correlate with HRQoL measures
in addition to PFT values, especially DLCO (data not
shown). The DSP is a calculation derived from 6MWD
and the lowest saturation at 6 min and has been shown
to predict poor outcome in patients with IPF [17]. We
conclude that HRQoL can best be predicted by DSP and
the BDSS at 6 min and that these two parameters may
be used as surrogates for HRQoL measures as deter-
mined by these two commonly used questionnaires. The
6MWT and dyspnea scores have previously been shown
to be correlated to improvements in HRQoL scores [18,
32, 37, 38]. A previous report addressed the reproduci-
bility of the 6MWT among patients with fibrotic lung
diseases and found that 6MWD is fairly reproducible.
Interestingly, although the amplitude of desaturation
among those patients varied, survival among those
patients best correlated with the amplitude of oxygen
desaturation as the strongest predictor of mortality [39].
The results of our study clearly demonstrate a significant
relationship between DSP and HRQoL scores as deter-
mined by either SF-36 or SHQ and that DSP is a better
predictor as compared with 6MWD.
Assessment of dyspnea is an important factor in evalu-
ating the functional status of patients with diverse dis-
eases and it has high impact on HRQoL scores [6, 37,
38]. Our findings concur with previous studies. Since ex-
ercise training and pulmonary rehabilitation may in-
crease exercise capacity, reduce dyspnea and increase
distance walked, these variables can be targeted for
intervention and may impact positively on outcomes
and HRQoL [37, 38].
Questionnaires designed to evaluate HRQoL have been
validated and have been shown to improve patient-
physician communication and counseling regarding
aspects of QoL [40]. Previous studies have found that PFT
values are not reliable markers to predict HRQoL in
patients with COPD [6, 7, 31]. In the current study, FEV1,
FVC and DLCO were found to have significant associations
with HRQoL scores on univariate analyses, but not in the
multiple regression models. No association was found be-
tween HRQoL scores and steroid use in our study, in
Table 4 Linear Regression DSP Multivariate Analysis with
SHQ and SF-36
Total SHQ Score Total SF −36 Score
Variable p value 95% CI p value 95% CI
DLCO 0.9 −0.01 - 0.02 0.5 −2.1 – 3.66
FEV1 0.7 −0.52 - 0.16 0.5 −2.2 – 0.44
DSP 0.009* 0.002 - 0.001 < 0.001* 0.082 – 0.02
Borg at 0 min 0.9 −0.06 - 0.7 0.14 −2.2 – 1.6
Borg at 6 min < 0.01* −0.27 – (−0.05) 0.049* −2.18 – (−1)
R2 = 0.24 R2 = 0.33
* Suggests statistically significant.
Table 5 Linear Regression Multivariate Analysis with SHQ
and SF-36
Total SHQ Score Total SF −36 Score
Variable p value 95% CI p value 95% CI
DLCO 0.6 −0.3 - 0.43 0.5 −2.1 - 3.66
FEV1 0.8 −0.33 - 0.26 0.6 −8.4 - 5.4
6MWD 0.01* 0.01 - 0.04 <0.01* 0.031 - 0.1
Borg at 0 min 0.9 −0.15 - 0.13 0.2 −5.5 - 0.16
Borg at 6 min 0.02* −0.06 – (−0.26) 0.04* −4.3 – (−0.16)
R2 = 0.22 R2= 0.26
* Suggests statistically significant.
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contradiction to earlier studies [33-35]. Patients with obes-
ity have also been shown to have poor HRQoL scores, but
no statistically significant association was found between
BMI and the HRQoL scores in our study [36, 41].
The SHQ is the only questionnaire specifically designed
to assess HRQoL in patients with sarcoidosis. It was ori-
ginally devised and validated with the SF-36 by Cox et al.
[4]. Our study independently validated the SHQ with the
SF-36 in a large cohort of patients with sarcoidosis. Add-
itionally, we compared the different domains assessed by
both questionnaires and found that the SHQ-PS corre-
lated well with SF-36-PCS, as did the SHQ-ES score with
SF-36-MCS. Because of its disease-specific nature, we
hypothesized that the SHQ would be a better measure of
HRQoL than the SF-36 in sarcoidosis patients. However,
this hypothesis was not supported by the evidence
reported here. One possibility is that the SHQ is differ-
ently weighted in regard to organ involvement as com-
pared with SF-36. SHQ would likely perform better than a
respiratory-specific measure of HRQoL, but we did not in-
clude this type of questionnaire in our study.
QoL is not only affected by disease severity, but also by
the social and occupational limitations imposed by the dis-
ease. Ethnicity may impact QoL in conditions like sarcoid-
osis due to its influence on both disease severity and
access to healthcare [42]. One limitation of this study is
that the sample consists almost entirely of African Ameri-
can women. Because of minimal variation in ethnicity
there may be racial differences not detected from this data
set.
This study is also limited by the fact that we could not
account for all comorbid conditions, including PH,
which may affect patients with sarcoidosis. Among the
study patients, 17% had known PH as confirmed by
right-sided cardiac catheterization (See Table 1). Re-
cently, we have shown that a decreased oxygen satur-
ation level at completion of 6MWT is highly predictive
of the presence PH in patients with sarcoidosis [16].
These patients also tend to have a lower oxygen satur-
ation resulting in a lower DSP. Additionally, we have not
assessed fatigue in this study, which has been shown to
be an important component of HRQoL and may impact
the 6MWD [43]. Overall, the correlation of HRQoL
measures and PFT values was lower as compared to cor-
relation of those measures with values derived from
6MWTs. This finding is not entirely surprising. Due to
the systemic nature of sarcoidosis, other systemic invol-
vements, besides lung function, such as musculoskeletal
involvement or fatigue may have contributed to the de-
crease in HRQoL measures. Finally, logistically we could
not always obtain the PFT, 6MWT and questionnaires
on the same day because of operational constraints at
our institution. This might be considered a limitation of
our study; although, it is unlikely that within weeks PFT
values or 6MWTwould have changed to the extent that
have influenced the results.
Our study is unique in attempting to identify com-
monly used clinical parameters as surrogate markers to
predict HRQoL in chronic sarcoidosis. The DSP and
BDSS at 6 min showed a significant association with
HRQoL scores and, therefore, may be used to predict
HRQoL in patients with sarcoidosis. These parameters
may serve as potential targets for intervention to im-
prove HRQoL. Further study is needed to validate the
value of DSP as a universal measure for the assessment
of HRQoL in other chronic respiratory diseases that lead
to oxygen desaturation during exertion, such as COPD
and IPF.
Conclusions
In conclusion, this study is among the first to identify
markers to predict HRQoL in patients with sarcoidosis.
The DSP and BDSS at 6 min are both easily obtained
from the 6MWT. This will allow clinicians to identify
patients who likely have poor HRQoL from an easily
performed clinical test and to target these variables for
intervention.
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